In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Hold rating on Pacira Pharmaceuticals (NASDAQ: PCRX), with a price target of $31. The company’s shares opened today at $35.20.
Rivkind Koffler wrote:
“We have switched from Symphony Health data, after a sizeable data restatement from the vendor rendered our prior estimates unreliable. April 2018 had one additional selling day vs. April 2017, in our view, so on a “units per selling day” basis, we calculate April 20 mL vials declined -2.8%.”
According to TipRanks.com, Koffler is a 5-star analyst with an average return of 13.2% and a 49.7% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Adamas Pharmaceuticals, Eagle Pharmaceuticals, and Jazz Pharmaceuticals.
Currently, the analyst consensus on Pacira Pharmaceuticals is Moderate Buy and the average price target is $46.45, representing a 32.0% upside.
In a report issued on May 17, Oppenheimer also assigned a Hold rating to the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $51.10 and a one-year low of $26.95. Currently, Pacira Pharmaceuticals has an average volume of 1.01M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. It develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
